Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 16/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 10/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26179644 | 1.00 | ABCG2 (0.51) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL21849411 | 0.94 | ABCG2 (0.53) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL15308223 | 0.94 | ABCG2 (0.53) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL31005176 | 0.94 | ABCG2 (0.53) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL15308256 | 0.93 | ABCG2 (0.50) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL21849412 | 0.93 | ABCG2 (0.50) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL31424086 | 0.93 | ABCG2 (0.50) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL29385966 | 0.93 | ABCG2 (0.50) | ABCG2ABCB1ABCC1MYCGABRA1 | |
| SCHEMBL29450769 | 0.92 | ABCG2 (0.54) | ABCG2ABCB1ABCC1GABRA1GABRG2 | |
| SCHEMBL21849416 | 0.92 | ABCG2 (0.54) | ABCG2ABCB1ABCC1GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192668-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE THEREOF | XPO4, OR10J3, EPB41 | ABCG2 908/4885ABCB1 321/4885ABCC1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.